Article Sidebar
Published:
Oct 28, 2022DOI:
10.4314/ahs.v22i3.42Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
Abstract
The efficacy of empagliflozin for non-alcoholic fatty liver disease remains controversial. This meta-analysis aims to explore the influence of empagliflozin versus placebo on the treatment of non-alcoholic fatty liver disease and we have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through July 2021 for related randomized controlled trials (RCTs). Three RCTs involving 212 patients are included in the meta-analysis. Compared with control group for non-alcoholic fatty liver disease, empagliflozin treatment has no improvement in controlled attenuation parameter (CAP) score, hepatic steatosis and liver stiffness measurement (LSM) score, alanine aminotransferase (ALT), aspartate-aminotransferase (AST), low density lipoprotein (LDL) or triglyceride (TG). These indicate that empagliflozin treatment may be not effective for non-alcoholic fatty liver disease.
Keywords: Empagliflozin; non-alcoholic fatty liver disease; randomized controlled trials; meta-analysis.
